These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1107 related articles for article (PubMed ID: 10496599)

  • 1. Ber-H2 (CD30) immunohistochemical staining in malignant melanoma.
    Polski JM; Janney CG
    Mod Pathol; 1999 Sep; 12(9):903-6. PubMed ID: 10496599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undifferentiated type and lymphoepithelioma-like carcinoma. A comparison study with anaplastic large cell lymphoma.
    Kneile JR; Tan G; Suster S; Wakely PE
    Histopathology; 2006 Jun; 48(7):855-61. PubMed ID: 16722935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
    Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
    Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary cutaneous CD30-positive anaplastic large cell lymphoma analysis.
    Shi Q; Zhou X; Yan X; Xu X; Yin H; Zhong T; Shamoto M; Qian B
    Chin Med J (Engl); 2002 Dec; 115(12):1802-5. PubMed ID: 12622927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy.
    Sung MT; Jones TD; Beck SD; Foster RS; Cheng L
    Hum Pathol; 2006 Jun; 37(6):662-7. PubMed ID: 16733205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical evaluation of CON6D/B5: a new CD30 monoclonal antibody.
    Lau SK; Thomas P; Weiss LM
    Appl Immunohistochem Mol Morphol; 2010 May; 18(3):273-7. PubMed ID: 20090517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule.
    Latza U; Foss HD; Dürkop H; Eitelbach F; Dieckmann KP; Loy V; Unger M; Pizzolo G; Stein H
    Am J Pathol; 1995 Feb; 146(2):463-71. PubMed ID: 7856755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases.
    Eyden B; Pandit D; Banerjee SS
    Histopathology; 2005 Oct; 47(4):402-9. PubMed ID: 16178895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
    Ulbright TM
    Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
    Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
    Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.
    Hofbauer GF; Schaefer C; Noppen C; Böni R; Kamarashev J; Nestle FO; Spagnoli GC; Dummer R
    Am J Pathol; 1997 Dec; 151(6):1549-53. PubMed ID: 9403705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
    Sedghizadeh PP; Williams JD; Allen CM; Prasad ML
    Med Sci Monit; 2005 Jul; 11(7):BR189-94. PubMed ID: 15990678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of HMB-45 and anti-Melan A staining of sentinel lymph nodes with isolated positive cells.
    Mahmood MN; Lee MW; Linden MD; Nathanson SD; Hornyak TJ; Zarbo RJ
    Mod Pathol; 2002 Dec; 15(12):1288-93. PubMed ID: 12481009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma.
    Gleason BC; Nascimento AF
    Am J Dermatopathol; 2007 Feb; 29(1):22-7. PubMed ID: 17284958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of CD15, CD30 & CD45 in the immunohistochemical diagnosis of Hodgkin's disease by antigen retrieval method.
    Arici DS; Aker H; Güngör M
    Indian J Med Res; 1999 Jan; 109():33-7. PubMed ID: 10489740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
    Isabel Zhu Y; Fitzpatrick JE
    J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
    Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
    Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland.
    Forconi F; Bocchia M; Marconcini S; Bigazzi C; Milani M; Fraternali-Orcioni G; Lauria F
    Haematologica; 1999 Oct; 84(10):946-8. PubMed ID: 10509044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
    Kageshita T; Ishihara T; Campoli M; Ferrone S
    Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD30 expression utilization for the accuracy of classical Hodgkin's lymphoma staging.
    Flangea C; Potencz E; Mihăescu R; Anghel A; Gîju S; Motoc M; Dogaru C
    Rom J Morphol Embryol; 2006; 47(2):113-7. PubMed ID: 17106517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.